Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide …

This guideline provides evidence-based recommendations for the treatment of tardive syndromes, focusing on effective management strategies and therapeutic interventions.

Oct 6, 2025 · Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder associated with the use of dopamine receptor-blocking agents, including first- and second …

Aug 19, 2024 · American Academy of Neurology (AAN) The American Academy of Neurology (AAN) guidelines for the treatment of tardive dyskinesia (TD) provide evidence-based …

TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter 2. * Level A is the strongest recommendation, established as effective, based on at least 2 consistent class I studies. Level …

3 days ago · From the Guidelines Tardive dyskinesia is best treated by first discontinuing the causative medication, if possible, and then using FDA-approved VMAT2 inhibitors, such as …

Abstract Background: Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. …

TD Treatment The Recommended Treatment Guidelines The 2020 American Psychological Association (APA) Practice Guideline recommends that patients with moderate-to-severe or …

Guidelines and Recommendations for Treatment of TD st-line treatment for tardive dyskinesia. These medications work by regulating the release of dopamine in the brain, which helps …

May 14, 2025 · The Clinician’s Tardive Inventory (CTI): a new clinical tool for documenting and rating tardive dyskinesia. J Clin Psychiatry. 2024;85 (1):23m14886. 12. Farber RH, Stull DE, …